Dusa Patent Suit Challenges Compounding Of Levulan
This article was originally published in The Pink Sheet Daily
Executive Summary
New England Compounding Center’s compounding of aminolevulinic acid HCl goes beyond the activities permitted under the FD&C Act, Dusa maintains. The company has also told FDA about its concerns.